Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $63,573,512 across 6 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2024-11-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-24-010733

Period
2024-09-30
Reported value
$63.6M
Holdings
6
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PASSAGE BIO INCexited-4,026,417-$3.2M
ALIGOS THERAPEUTICS INC COM…exited-1,457,937-$510K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2024

Share positions as resolved from 13F-HR 0000950123-24-010733, largest first. % of portfolio is the value over $63,573,512, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 498,558 shares 498,558$23.4M36.84%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 918,163 shares 918,163$17.6M27.64%0Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,646,657 shares 2,646,657$9.1M14.32%0
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,007,704 shares 2,007,704$7.85M12.35%0Timeline
Adverum Biotechnologies, In…Adverum Biotechnologies, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 506,821 shares 506,821$3.56M5.6%0
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,561,150 shares 3,561,150$2.07M3.25%0

Sold out in Q3 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PASSAGE BIO INCPASSAGE BIO INC4,026,417$3.2Mshares
ALIGOS THERAPEUTICS INC COM…ALIGOS THERAPEUTICS INC COM NEW1,457,937$510Kshares

How Q3 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-24-010733 base2024-11-08acceptance time not in the bulk data set